Cargando…

Cohort profile: cholangiocarcinoma screening and care program (CASCAP)

BACKGROUND: Cholangiocarcinoma (CCA) is an extremely aggressive cancer that is usually fatal. Although globally morbidity and mortality are increasing, knowledge of the disease remains limited. The Mekong region of Southeast Asia, and particularly the northeast of Thailand, has by far the highest in...

Descripción completa

Detalles Bibliográficos
Autores principales: Khuntikeo, Narong, Chamadol, Nittaya, Yongvanit, Puangrat, Loilome, Watcharin, Namwat, Nisana, Sithithaworn, Paiboon, Andrews, Ross H., Petney, Trevor N., Promthet, Supannee, Thinkhamrop, Kavin, Tawarungruang, Chaiwat, Thinkhamrop, Bandit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459438/
https://www.ncbi.nlm.nih.gov/pubmed/26054405
http://dx.doi.org/10.1186/s12885-015-1475-7
_version_ 1782375221920006144
author Khuntikeo, Narong
Chamadol, Nittaya
Yongvanit, Puangrat
Loilome, Watcharin
Namwat, Nisana
Sithithaworn, Paiboon
Andrews, Ross H.
Petney, Trevor N.
Promthet, Supannee
Thinkhamrop, Kavin
Tawarungruang, Chaiwat
Thinkhamrop, Bandit
author_facet Khuntikeo, Narong
Chamadol, Nittaya
Yongvanit, Puangrat
Loilome, Watcharin
Namwat, Nisana
Sithithaworn, Paiboon
Andrews, Ross H.
Petney, Trevor N.
Promthet, Supannee
Thinkhamrop, Kavin
Tawarungruang, Chaiwat
Thinkhamrop, Bandit
author_sort Khuntikeo, Narong
collection PubMed
description BACKGROUND: Cholangiocarcinoma (CCA) is an extremely aggressive cancer that is usually fatal. Although globally morbidity and mortality are increasing, knowledge of the disease remains limited. The Mekong region of Southeast Asia, and particularly the northeast of Thailand, has by far the highest incidence of CCA worldwide with 135.4 per 100,000 among males and 43.0 per 100,000 among females being reported in Khon Kaen Province. Most patients are first seen during late stage disease with 5-year survival being less than 10 %. Starting in 1984, control and prevention strategies have been focused on health education. Although early detection can substantially increase 5-year survival, there are currently no strategies to increase early diagnosis. METHODS/DESIGN: The Cholangiocarcinoma Screening and Care Program (CASCAP) is a prospective cohort study comprising two cohorts- the screening and the patient cohorts. For the screening cohort, ultrasound examination will be carried out regularly at least annually to determine whether there is current bile duct and/or liver pathology so that the optimal screening program for early diagnosis can be established. This cohort is expected to include at least 150,000 individuals coming from high-risk areas for CCA. For the patient cohort, it is estimated that about 25,000 CCA patients will be included during the 5-year recruitment period. All CCA patients will be treated according to routine clinical care and followed so that effective surgical treatment can be formulated. This cohort is indeed a conventional cancer registry. Thus, CASCAP is an ongoing project in which the number of participants changes dynamically. DISCUSSIONS: This is the first project on CCA that involves screening the at risk population at the community level. At the time of preparing this report, a total of 85,927 individuals have been enrolled in the screening cohort, 55.0 % of whom have already undergone ultrasound screening, and 2661 CCA cases have been enrolled in the patient cohort. Among the participants of the screening, whose mean age was 53.8 ± 9.8 years, 55.6 % were female, 77.5 % attained primary school as the highest level of education, 79.9 % were farmers, 29.9 %, reported having relatives with CCA, 89.1 % had eaten uncooked fish, and 42.2 % of those who had been tested for liver fluke were found to be infected.
format Online
Article
Text
id pubmed-4459438
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44594382015-06-09 Cohort profile: cholangiocarcinoma screening and care program (CASCAP) Khuntikeo, Narong Chamadol, Nittaya Yongvanit, Puangrat Loilome, Watcharin Namwat, Nisana Sithithaworn, Paiboon Andrews, Ross H. Petney, Trevor N. Promthet, Supannee Thinkhamrop, Kavin Tawarungruang, Chaiwat Thinkhamrop, Bandit BMC Cancer Study Protocol BACKGROUND: Cholangiocarcinoma (CCA) is an extremely aggressive cancer that is usually fatal. Although globally morbidity and mortality are increasing, knowledge of the disease remains limited. The Mekong region of Southeast Asia, and particularly the northeast of Thailand, has by far the highest incidence of CCA worldwide with 135.4 per 100,000 among males and 43.0 per 100,000 among females being reported in Khon Kaen Province. Most patients are first seen during late stage disease with 5-year survival being less than 10 %. Starting in 1984, control and prevention strategies have been focused on health education. Although early detection can substantially increase 5-year survival, there are currently no strategies to increase early diagnosis. METHODS/DESIGN: The Cholangiocarcinoma Screening and Care Program (CASCAP) is a prospective cohort study comprising two cohorts- the screening and the patient cohorts. For the screening cohort, ultrasound examination will be carried out regularly at least annually to determine whether there is current bile duct and/or liver pathology so that the optimal screening program for early diagnosis can be established. This cohort is expected to include at least 150,000 individuals coming from high-risk areas for CCA. For the patient cohort, it is estimated that about 25,000 CCA patients will be included during the 5-year recruitment period. All CCA patients will be treated according to routine clinical care and followed so that effective surgical treatment can be formulated. This cohort is indeed a conventional cancer registry. Thus, CASCAP is an ongoing project in which the number of participants changes dynamically. DISCUSSIONS: This is the first project on CCA that involves screening the at risk population at the community level. At the time of preparing this report, a total of 85,927 individuals have been enrolled in the screening cohort, 55.0 % of whom have already undergone ultrasound screening, and 2661 CCA cases have been enrolled in the patient cohort. Among the participants of the screening, whose mean age was 53.8 ± 9.8 years, 55.6 % were female, 77.5 % attained primary school as the highest level of education, 79.9 % were farmers, 29.9 %, reported having relatives with CCA, 89.1 % had eaten uncooked fish, and 42.2 % of those who had been tested for liver fluke were found to be infected. BioMed Central 2015-06-09 /pmc/articles/PMC4459438/ /pubmed/26054405 http://dx.doi.org/10.1186/s12885-015-1475-7 Text en © Khuntikeo et al. 2015 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Study Protocol
Khuntikeo, Narong
Chamadol, Nittaya
Yongvanit, Puangrat
Loilome, Watcharin
Namwat, Nisana
Sithithaworn, Paiboon
Andrews, Ross H.
Petney, Trevor N.
Promthet, Supannee
Thinkhamrop, Kavin
Tawarungruang, Chaiwat
Thinkhamrop, Bandit
Cohort profile: cholangiocarcinoma screening and care program (CASCAP)
title Cohort profile: cholangiocarcinoma screening and care program (CASCAP)
title_full Cohort profile: cholangiocarcinoma screening and care program (CASCAP)
title_fullStr Cohort profile: cholangiocarcinoma screening and care program (CASCAP)
title_full_unstemmed Cohort profile: cholangiocarcinoma screening and care program (CASCAP)
title_short Cohort profile: cholangiocarcinoma screening and care program (CASCAP)
title_sort cohort profile: cholangiocarcinoma screening and care program (cascap)
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459438/
https://www.ncbi.nlm.nih.gov/pubmed/26054405
http://dx.doi.org/10.1186/s12885-015-1475-7
work_keys_str_mv AT khuntikeonarong cohortprofilecholangiocarcinomascreeningandcareprogramcascap
AT chamadolnittaya cohortprofilecholangiocarcinomascreeningandcareprogramcascap
AT yongvanitpuangrat cohortprofilecholangiocarcinomascreeningandcareprogramcascap
AT loilomewatcharin cohortprofilecholangiocarcinomascreeningandcareprogramcascap
AT namwatnisana cohortprofilecholangiocarcinomascreeningandcareprogramcascap
AT sithithawornpaiboon cohortprofilecholangiocarcinomascreeningandcareprogramcascap
AT andrewsrossh cohortprofilecholangiocarcinomascreeningandcareprogramcascap
AT petneytrevorn cohortprofilecholangiocarcinomascreeningandcareprogramcascap
AT promthetsupannee cohortprofilecholangiocarcinomascreeningandcareprogramcascap
AT thinkhamropkavin cohortprofilecholangiocarcinomascreeningandcareprogramcascap
AT tawarungruangchaiwat cohortprofilecholangiocarcinomascreeningandcareprogramcascap
AT thinkhamropbandit cohortprofilecholangiocarcinomascreeningandcareprogramcascap
AT cohortprofilecholangiocarcinomascreeningandcareprogramcascap